ine life as depicted by them. This can lead to better understanding of an individual person's needs and increase the quality of care provided.There are no FDA-approved treatments for cannabis use disorder (CUD). Preclinical research has shown that the 5HT-2C agonist lorcaserin attenuates cue-induced reinstatement of THC seeking and self-administration. The goal of this placebo-controlled, counterbalanced, within-subject human laboratory study was to examine lorcaserin's effects on cannabis intoxication and self-administration. Lorcaserin (10 mg BID) was administered during one of two 13-day inpatient phases and placebo during the other; each phase was separated by ?7 days of washout. Inpatient phases comprised (1) standardized cannabis administration (7.0% THC) at no financial cost (intoxication), counterbalanced with (2) the option to self-administer cannabis following either 0 or 3 days of abstinence. Cognitive task performance, food intake, subjective ratings of drug effects, objective/subjective sleep measures, and tobacco cigarette use were also assessed. Fifteen normal-weight, daily cannabis users (4F, 11M) not seeking treatment for CUD completed the study. Lorcaserin significantly reduced cannabis self-administration following 0 and 3 days of cannabis abstinence and also reduced craving for cannabis during abstinence. Lorcaserin produced small but significant increases in positive cannabis ratings and body weight relative to placebo. Lorcaserin also reduced tobacco cigarette smoking on days of cannabis administration relative to placebo. During abstinence, subjective but not objective measures of sleep quality worsened during lorcaserin maintenance. Overall, lorcaserin's ability to decrease drug taking and cannabis craving in nontreatment-seeking cannabis users supports further investigation of 5HT-2C agonists as potential pharmacotherapies for CUD.Warts are small, benign growths caused by human papilloma virus. No treatment has yet proven 100% effective for a cure. DNA viruses rely on K+influx for replication. Both digoxin and furosemide inhibit the K+influx by interacting with cell membrane ion co-transporters. Therefore, it is hypothesized that these two compounds may be valuable in the treatment of warts.
Our aim was to evaluate the efficacy and safety of intralesional injection of a combination of digoxin and furosemide in treatment of plantar warts.
This two-armed single blinded randomized clinical trial included 40 cases with multiple plantar warts (?3warts) divided into 2 groups (20 cases each). The first group received intralesional normal saline and the second group received intralesional combined digoxin and furosemide, one session every week for maximum 5 injection sessions.
On comparing between the 2 groups regarding response to treatment (reduction in number of warts), the first group showed no change in number of warts (82 warts before and after treatment), whereas, in the second group, the number of warts before treatment was 80 while after treatment it was 40 (50% reduction in number). There was a statistically significant difference between the two groups as regard the change in the total number of warts (P&lt;.001).
Intralesional injection of combined digoxin and furosemide is safe and effective treatment option in multiple plantar warts.
Intralesional injection of combined digoxin and furosemide is safe and effective treatment option in multiple plantar warts.Diffuse large B-cell lymphoma (DLBCL) is the most common category of non-Hodgkin lymphoma (NHL). However, the underlying molecular mechanism of DLBCL remains unclear.
Real-time PCR and Western blot analysis were performed to assess the expression of ubiquitin-specific peptidase 21 (USP21) or enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2). https://www.selleckchem.com/products/syrosingopine-su-3118.html CCK8 assay and cell death staining were carried out to examine the role of USP21 in cell proliferation and cell death, respectively.
We found that the deubiquitinase USP21 was highly expressed in the DLBCL lymphoid tissue. The expression of USP21 promoted DLBCL cell proliferation, while it had no obvious effect on cell death. In addition, we found that USP21 regulated cell proliferation via cysteine 221, the catalytic site of USP21. Furthermore, we identified that USP21 could stabilize EZH2, a protein required for germinal center formation and lymphoma formation.
The deubiquitinase USP21 promotes cell proliferation by maintaining the EZH2 protein level in DLBCL.
The deubiquitinase USP21 promotes cell proliferation by maintaining the EZH2 protein level in DLBCL.Cancer survivors may experience multiple comorbidities related to the disease itself and adverse effects from treatment. Rehabilitation specialists could provide treatment options; however, oncologic rehabilitation services are underutilized.
To assess oncologists' awareness of the benefits of rehabilitation for cancer care patients and to identify barriers to rehabilitation referrals in adult cancer patients in Puerto Rico.
Cross-sectional study.
Regional Annual Meeting of the Association of Medical Hematology and Oncology of Puerto Rico, 4-7 September 2015.
Forty-two oncologists.
Participants completed a 10-item questionnaire focused on demographics, knowledge, and clinical practices over the previous 12?months related to rehabilitation in cancer patients.
Frequency, reasons, and timing for oncologist referral of cancer patients to rehabilitation. Perceived risks and benefits of rehabilitation in cancer patients and their correlation to patient referrals, prognosis, type of cancer, and type ofl for their patients, there is a low referral rate. This could be due to lack of information about cancer rehabilitation and limited access to cancer rehabilitation specialists. Further efforts should be made to improve access to rehabilitation care for cancer patients and survivors.Moral courage and understanding of its meaning are essential when nurses face ethical conflicts in their practice. This integrative review aimed to explore moral courage in nursing and possible associated individual and organizational factors. A database search in January 2020 identified 1308 scientific articles of which 25 were selected for the review. Inductive analysis with clear steps for defining and synthesizing themes in research reviews revealed three categories concerning moral courage in nursing definition and descriptions of moral courage, characteristics of the morally courageous nurse, and skills and acts of the morally courageous nurse. Individual and organizational factors, such as positive personal experiences, commitment to ethical principles, supportive work environment and teamwork, were associated with moral courage in nursing, contributing to a more comprehensive description of nurses' moral courage. Findings indicate that in nursing practice, there is a need for promoting multi-professional collaboration and discussion of ethical dilemmas to provide opportunities to enhance moral courage.